

Imatinib (Glivec[®])

(No. 26/02)

Novartis

Summary of Recommendation

10 January 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for restricted use within NHS Scotland.

RECOMMENDATION

This licence extension has been granted on the basis of interim analyses which show superiority of imatinib over interferon combination therapy in terms of cytogenetic and haematological response.

Imatinib should be used only by or under the direction of haematologists/oncologists experienced in this field. There should be a formal process of audit and monitoring with a central registry of all patients receiving it and/or entry into a clinical trial.

D H Lawson
Chairman